HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 4 (2007), Issue 3 (March)

1. Molecular programming of endothelin-1 in HIV-infected brain: role of Tat in up-regulation of ET-1 and its inhibition by statins.
   FASEB J, 21(3): 777-89. [Abstract] [Full-text]
2. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
   Pediatrics, 119(3): e705-15. [Abstract] [Full-text]
3. Infectious disease morbidity among young HIV-1-exposed but uninfected infants in Latin American and Caribbean countries: the National Institute of Child Health and Human Development International Site Development Initiative Perinatal Study.
   Pediatrics, 119(3): e694-704. [Abstract] [Full-text]
4. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy.
   Pediatrics, 119(3): e681-93. [Abstract] [Full-text]
5. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.
   J Infect Dis, 195(7): 973-9. [Abstract] [Full-text]
6. Breast milk CD4+ T cells express high levels of C chemokine receptor 5 and CXC chemokine receptor 4 and are preserved in HIV-infected mothers receiving highly active antiretroviral therapy.
   J Infect Dis, 195(7): 965-72. [Abstract] [Full-text]
7. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals.
   J Infect Dis, 195(7): 960-4. [Abstract] [Full-text]
8. High rates of forward transmission events after acute/early HIV-1 infection.
   J Infect Dis, 195(7): 951-9. [Abstract] [Full-text]
9. Microbicide drug candidates to prevent HIV infection.
   Lancet, 369(9563): 787-97. [Abstract] [Full-text]
10. HIV infection with concomitant cerebral toxoplasmosis and disseminated histoplasmosis in a 45-year-old man.
    J Infect Chemother, 13(1): 51-5. [Abstract] [Full-text]
11. Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features.
    J Infect Chemother, 13(1): 1-7. [Abstract] [Full-text]
12. LEDGF/p75 interferes with the formation of synaptic nucleoprotein complexes that catalyze full-site HIV-1 DNA integration in vitro: implications for the mechanism of viral cDNA integration.
    Virology, 360(1): 1-5. [Abstract] [Full-text]
13. Characterization of HIV-1 integrase N-terminal mutant viruses.
    Virology, 360(1): 129-35. [Abstract] [Full-text]
14. Mutations in the V3 stem versus the V3 crown and C4 region have different effects on the binding and fusion steps of human immunodeficiency virus type 1 gp120 interaction with the CCR5 coreceptor.
    Virology, 360(1): 182-90. [Abstract] [Full-text]
15. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.
    Virology, 360(1): 218-34. [Abstract] [Full-text]
16. A 2a/1b full-length p7 inter-genotypic chimeric genome of hepatitis C virus is infectious in vitro.
    Virology, 360(1): 17-26. [Abstract] [Full-text]
17. Double-labelled HIV-1 particles for study of virus-cell interaction.
    Virology, 360(1): 92-104. [Abstract] [Full-text]
18. Depletion of cellular cholesterol inhibits membrane binding and higher-order multimerization of human immunodeficiency virus type 1 Gag.
    Virology, 360(1): 27-35. [Abstract] [Full-text]
19. Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1.
    Virology, 360(1): 199-208. [Abstract] [Full-text]
20. Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion.
    Virology, 360(1): 105-19. [Abstract] [Full-text]
21. Poor health kills small business: illness and microenterprises in South Africa.
    Health Aff (Millwood), 26(2): 474-82. [Abstract] [Full-text]
22. Absence of Y-chromosome sequences in tumors from African women with AIDS-related Kaposi sarcoma.
    Cancer Lett, 248(2): 229-33. [Abstract] [Full-text]
23. Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis.
    Clin Infect Dis, 44(7): 1001-8. [Abstract] [Full-text]
24. Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy?
    Clin Infect Dis, 44(7): 996-1000. [Abstract] [Full-text]
25. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.
    Clin Infect Dis, 44(7): 988-95. [Abstract] [Full-text]
26. HIV epidemiology update and transmission factors: risks and risk contexts--16th International AIDS Conference epidemiology plenary.
    Clin Infect Dis, 44(7): 981-7. [Abstract] [Full-text]
27. Increased mitochondrial mass characterizes the survival defect of HIV-specific CD8(+) T cells.
    Blood, 109(6): 2505-13. [Abstract] [Full-text]
28. Spectrum and presentation of pediatric malignancies in the HIV era: experience from Blantyre, Malawi, 1998-2003.
    Pediatr Blood Cancer, 48(5): 515-20. [Abstract] [Full-text]
29. Trans-inhibition of HIV-1 by a long hairpin RNA expressed within the viral genome.
    Retrovirology, 4: 15. [Abstract] [Full-text]
30. Mechanically-evoked C-fiber activity in painful alcohol and AIDS therapy neuropathy in the rat.
    Mol Pain, 3: 5. [Abstract] [Full-text]
31. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV.
    Am J Med, 120(3): 272-9. [Abstract] [Full-text]
32. Structural and biochemical studies of ALIX/AIP1 and its role in retrovirus budding.
    Cell, 128(5): 841-52. [Abstract] [Full-text]
33. Biophysical characterization of V3-lipopeptide liposomes influencing HIV-1 infectivity.
    Biochem Biophys Res Commun, 355(4): 963-9. [Abstract] [Full-text]
34. Prevalence of complications of male circumcision in Anglophone Africa: a systematic review.
    BMC Urol, 7: 4. [Abstract] [Full-text]
35. Time frames for neutralization during the human immunodeficiency virus type 1 entry phase, as monitored in synchronously infected cell cultures.
    J Virol, 81(7): 3525-34. [Abstract] [Full-text]
36. Distinct transcriptional profiles in ex vivo CD4+ and CD8+ T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD8+ T cells.
    J Virol, 81(7): 3477-86. [Abstract] [Full-text]
37. Inhibition of human immunodeficiency virus type 1 infection of human CD4+ T cells by microbial HSP70 and the peptide epitope 407-426.
    J Virol, 81(7): 3354-60. [Abstract] [Full-text]
38. Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor.
    J Virol, 81(7): 3645-8. [Abstract] [Full-text]
39. Modest human immunodeficiency virus coreceptor function of CXCR3 is strongly enhanced by mimicking the CXCR4 ligand binding pocket in the CXCR3 receptor.
    J Virol, 81(7): 3632-9. [Abstract] [Full-text]
40. Frequent intrapatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for coreceptor switch.
    J Virol, 81(7): 3369-76. [Abstract] [Full-text]
41. Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication.
    J Virol, 81(7): 3465-76. [Abstract] [Full-text]
42. Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes.
    J Virol, 81(7): 3667-72. [Abstract] [Full-text]
43. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.
    J Virol, 81(7): 3240-50. [Abstract] [Full-text]
44. Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4+ T cells.
    J Virol, 81(7): 3574-82. [Abstract] [Full-text]
45. New way of regulating alternative splicing in retroviruses: the promoter makes a difference.
    J Virol, 81(7): 3652-6. [Abstract] [Full-text]
46. An extended stem-loop 1 is necessary for human immunodeficiency virus type 2 replication and affects genomic RNA encapsidation.
    J Virol, 81(7): 3285-92. [Abstract] [Full-text]
47. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
    J Virol, 81(7): 3414-27. [Abstract] [Full-text]
48. Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations.
    J Virol, 81(7): 3657-61. [Abstract] [Full-text]
49. Fluorescent HIV-1 Dimerization Initiation Site: design, properties, and use for ligand discovery.
    J Am Chem Soc, 129(11): 3257-66. [Abstract] [Full-text]
50. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis.
    J Infect Dis, 195(8): 1181-3. [Abstract] [Full-text]
51. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads.
    J Infect Dis, 195(8): 1177-80. [Abstract] [Full-text]
52. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.
    J Infect Dis, 195(8): 1169-76. [Abstract] [Full-text]
53. Epidemiological features of HIV infection among pregnant women in Makurdi, Benue State, Nigeria.
    J Biosoc Sci, 39(3): 397-408. [Abstract] [Full-text]
54. HIV/AIDS knowledge, women's education, epidemic severity and protective sexual behaviour in low- and middle-income countries.
    J Biosoc Sci, 39(3): 421-42. [Abstract] [Full-text]
55. Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: a meta-analysis.
    Clin Infect Dis, 44(8): 1123-31. [Abstract] [Full-text]
56. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men.
    Clin Infect Dis, 44(8): 1115-22. [Abstract] [Full-text]
57. Founder effects in the assessment of HIV polymorphisms and HLA allele associations.
    Science, 315(5818): 1583-6. [Abstract] [Full-text]
58. Suppression of microRNA-silencing pathway by HIV-1 during virus replication.
    Science, 315(5818): 1579-82. [Abstract] [Full-text]
59. Health risk behaviors among HIV-infected youth in Bangkok, Thailand.
    J Adolesc Health, 40(4): 358.e1-8. [Abstract] [Full-text]
60. Arrest history as an indicator of adolescent/young adult substance use and HIV risk.
    Drug Alcohol Depend, 88(1): 87-90. [Abstract] [Full-text]
61. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial.
    Drug Alcohol Depend, 88(1): 54-63. [Abstract] [Full-text]
62. Optimisation and parallelisation strategies for Monte Carlo simulation of HIV infection.
    Comput Biol Med, 37(5): 691-9. [Abstract] [Full-text]
63. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.
    BMC Infect Dis, 7: 14. [Abstract] [Full-text]
64. Investigational agents for treatment of AIDS-related Kaposi's sarcoma.
    Expert Opin Investig Drugs, 16(4): 495-504. [Abstract] [Full-text]
65. Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor.
    Proc Natl Acad Sci U S A, 104(12): 5097-102. [Abstract] [Full-text]
66. Human herpesvirus 6A accelerates AIDS progression in macaques.
    Proc Natl Acad Sci U S A, 104(12): 5067-72. [Abstract] [Full-text]
67. Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients.
    Clin Pharmacol Ther, 81(4): 580-5. [Abstract] [Full-text]
68. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.
    Clin Pharmacol Ther, 81(4): 557-66. [Abstract] [Full-text]
69. Who's in and who's out: use of primary medical care among people living with HIV.
    Am J Public Health, 97(4): 744-9. [Abstract] [Full-text]
70. Atazanavir: simplicity and convenience in different scenarios.
    Expert Opin Pharmacother, 8(5): 689-700. [Abstract] [Full-text]
71. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment.
    Expert Opin Pharmacother, 8(5): 679-88. [Abstract] [Full-text]
72. Purulent pericarditis due to co-infection with Streptococcus pneumoniae and Mycobacterium tuberculosis in a patient with features of advanced HIV infection.
    BMC Infect Dis, 7: 12. [Abstract] [Full-text]
73. Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8).
    Qual Life Res, 16(4): 577-91. [Abstract] [Full-text]
74. Impact of joined-up HIV harm reduction and multidrug resistant tuberculosis control programmes in Estonia: System dynamics simulation model.
    Health Policy, 81(2): 207-17. [Abstract] [Full-text]
75. Modelling the public health impact of male circumcision for HIV prevention in high prevalence areas in Africa.
    BMC Infect Dis, 7: 16. [Abstract] [Full-text]
76. Assessing health-related quality of life in NeuroAIDS: some psychometric properties of the Neurological Quality of Life Questionnaire (NeuroQOL).
    J Clin Neurosci, 14(5): 416-23. [Abstract] [Full-text]
77. Prevention of mother to child transmission of HIV infection in Pacific countries.
    Intern Med J, 37(4): 216-23. [Abstract] [Full-text]
78. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
    Arch Intern Med, 167(6): 597-605. [Abstract] [Full-text]
79. Sex-structured HIV/AIDS model to analyse the effects of condom use with application to Zimbabwe.
    J Math Biol, 54(5): 669-99. [Abstract] [Full-text]
80. Post-evaluation of rapid HIV kits in the Korean market by an anti-HIV EQAS panel.
    J Virol Methods, 141(2): 141-5. [Abstract] [Full-text]

© 2004-2010 HIV Research Today. All Rights Reserved.